

IN THE CLAIMS

1. (currently amended) A method of producing an immune response in a mammal, comprising the step of:

in (i.e., intranasally)

administering mucosally to a mammal an admixture comprising ~~an~~ a protein immunogen and a plant lectin, whereby the mammal produces an immune response to the protein immunogen which is greater relative to the immune response to the protein immunogen produced in the absence of the plant lectin.

2. (canceled)

3. (currently amended) The method of claim 1 wherein the admixture is administered intranasally.

012 4. (currently amended) The method of claim 1 wherein the plant lectin is ~~selected from the group consisting of~~ ML-I, ML-II, ML-III, WGA, and UEA-I.

5. (original) The method of claim 1 wherein the mammal is selected from the group consisting of a dog, a cat, a mouse, a rat, a rabbit, a guinea pig, a chimpanzee, a baboon, and a human.

6. (original) The method of claim 1 wherein the immune response is a T cell response.

01 7. (original) The method of claim 6 wherein the T cell response is a Th2 response.

8. (original) The method of claim 6 wherein the T cell response is proliferation of T cells.

9. (original) The method of claim 1 wherein the immune response is an antibody response.

10. (currently amended) The method of claim 9 wherein the ~~mammal produces an antibody which is selected from the group consisting of~~ response is an IgG response and IgA antibodies.

11. (currently amended) The method of claim 10 wherein the IgG antibodies are ~~selected from the group consisting of IgG1 antibodies, IgG2a, and IgG2b.~~

12. (original) The method of claim 10 wherein the antibodies are detectable in serum.

13. (original) The method of claim 10 wherein the antibodies are detectable in mucosal secretion.

14. (currently amended) The method of claim 13 wherein the mucosal secretion is obtained from a ~~mucosa selected from the group consisting of gut mucosa, vaginal mucosa, oral mucosa, and nasal mucosa.~~

15. (currently amended) The method of claim 1 wherein the admixture comprises two or more different lectins.

16. (currently amended) The method of claim 1 wherein the admixture comprises two or more different immunogens.

17. (currently amended) The method of claim 1 wherein the protein immunogen is a protein of an infectious agent.

18. (currently amended) The method of claim 17 ~~20~~ wherein the infectious agent is a virus.

19. (currently amended) The method of claim 17 ~~24~~ wherein the immunogen is a glycoprotein D2 protein from a *Herpes simplex* virus type 2.

20. (original) The method of claim 3 wherein the admixture is administered using a nasal spray.

21. (original) The method of claim 3 wherein a drop of a liquid containing the admixture is administered.

22. (original) The method of claim 1 wherein at least two doses of the admixture are administered.

23. (currently amended) The method of claim 1 wherein the admixture comprises ~~an~~ a protein immunogen and a plant lectin in a ratio of at least about 1:1.

24. (currently amended) The method of claim 23 ~~26~~ wherein the ratio is at least about 10:1.

25. (original) The method of claim 9 wherein an antibody titer is measured using an ELISA.

26. (canceled)

27. (original) The method of claim 1 wherein the plant lectin is a type 2 ribosome inactivating protein.

28. (currently amended) The method of claim 27 ~~30~~ wherein the type 2 ribosome inactivating protein is selected from the group consisting of nigrin b, basic nigrin b, ebulin 1, ebulin r1, ebulin r, ebulin f, nigrin f, SNA1, SNA1, SNAV, SNAVI, Sambucus nigra SNLRP1, SNLRP2, ricin, Ricinus lectin, Polygonatum RIP, Sieboldin-6, abrin, abrin 11, modeccin, volkensin, SSA, Cinnamomin, porrectin, gelorin, Evanthis hyemalis, RIP, Iris agglutinin, ML-I, ML-II, and ML-III.

29. (canceled)

30. (original) The method of claim 1 wherein the admixture is administered in conjunction with a bioadhesive polymer.

31. (original) The method of claim 1 wherein the admixture is in an enteric formulation.

OK 32. (new) The method of claim 1 wherein the plant lectin is ML-II.

OK 33. (new) The method of claim 1 wherein the plant lectin is ML-III.

34. (new) The method of claim 1 wherein the plant lectin is WGA.

OK 35. (new) The method of claim 1 wherein the plant lectin is UEA-1.

36. (new) The method of claim 5 wherein the mammal is a mouse.

37. (new) The method of claim 5 wherein the mammal is a human.

38. (new) The method of claim 9 wherein the antibody response is an IgA response.

39. (new) The method of claim 10 wherein the IgG antibodies are IgG2a antibodies.

40. (new) The method of claim 10 wherein the IgG antibodies are IgG2b antibodies.

41. (new) The method of claim 13 wherein the mucosal secretion is obtained from a vaginal mucosa.

42. (new) The method of claim 13 wherein the mucosal secretion is obtained from an oral mucosa

43. (new) The method of claim 13 wherein the mucosal secretion is obtained from a nasal mucosa.

UEA: ULRUK EUROPAEUS AGGLUTININ (UEA-I)

ML: MISTLETOE LECTIN (ML-I, ML-II, ML-III)